Harborside


MediPharm Labs Corp.

TSE: LABS


Canadian symbol: LABS.TO
US symbol: MEDIF

Currency in CAD

Valuation Measures4

Market Cap (intraday) 51.55M
Enterprise Value 15.84M
Trailing P/E 187.00
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)1.99
Price/Book (mrq)0.53
Enterprise Value/Revenue 0.72
Enterprise Value/EBITDA -0.42

Trading Information

Stock Price History

Beta (5Y Monthly) 0.78
52-Week Change 3-67.50%
S&P500 52-Week Change 322.93%
52 Week High 31.0000
52 Week Low 30.1950
50-Day Moving Average 30.2596
200-Day Moving Average 30.4021

Share Statistics

Avg Vol (3 month) 3499.22k
Avg Vol (10 day) 3472.59k
Shares Outstanding 5264.34M
Implied Shares Outstanding 6N/A
Float 8237.83M
% Held by Insiders 16.47%
% Held by Institutions 118.78%
Shares Short (Nov. 14, 2021) 47.12M
Short Ratio (Nov. 14, 2021) 413.48
Short % of Float (Nov. 14, 2021) 4N/A
Short % of Shares Outstanding (Nov. 14, 2021) 42.69%
Shares Short (prior month Oct. 14, 2021) 47.78M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2020
Most Recent Quarter (mrq)Sep. 29, 2021

Profitability

Profit Margin -290.50%
Operating Margin (ttm)-255.38%

Management Effectiveness

Return on Assets (ttm)-26.19%
Return on Equity (ttm)-61.86%

Income Statement

Revenue (ttm)22.03M
Revenue Per Share (ttm)0.10
Quarterly Revenue Growth (yoy)9.20%
Gross Profit (ttm)-44.42M
EBITDA -46.49M
Net Income Avi to Common (ttm)-63.99M
Diluted EPS (ttm)-0.3010
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)37.96M
Total Cash Per Share (mrq)0.14
Total Debt (mrq)2.25M
Total Debt/Equity (mrq)2.20
Current Ratio (mrq)5.49
Book Value Per Share (mrq)0.39

Cash Flow Statement

Operating Cash Flow (ttm)-16.49M
Levered Free Cash Flow (ttm)-11.48M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
LABS.TO
MediPharm Labs
2 weeks ago
LABS.TO
MediPharm Labs
2 weeks ago
LABS.TO
MediPharm Labs
2 weeks ago
LABS.TO
MediPharm Labs
3 weeks ago
LABS.TO
MediPharm Labs
3 months ago
LABS.TO
MediPharm Labs
3 months ago
LABS.TO
MediPharm Labs
3 months ago
LABS.TO
MediPharm Labs
3 months ago
LABS.TO
MediPharm Labs
4 months ago
LABS.TO
MediPharm Labs
4 months ago
LABS.TO
MediPharm Labs
4 months ago
LABS.TO
MediPharm Labs
6 months ago
LABS.TO
MediPharm Labs
6 months ago
LABS.TO
MediPharm Labs
6 months ago
LABS.TO
MediPharm Labs
8 months ago
LABS.TO
MediPharm Labs
8 months ago
LABS.TO
MediPharm Labs
8 months ago
LABS.TO
MediPharm Labs
8 months ago
LABS.TO
MediPharm Labs
9 months ago
LABS.TO
MediPharm Labs
9 months ago
LABS.TO
MediPharm Labs
9 months ago
LABS.TO
MediPharm Labs
9 months ago
LABS.TO
MediPharm Labs
9 months ago
LABS.TO
MediPharm Labs
10 months ago
LABS.TO
MediPharm Labs
10 months ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago

Currency in CAD
Earnings EstimateCurrent Qtr. (Dec 2021)Next Qtr. (Mar 2022)Current Year (2021)Next Year (2022)
No. of Analysts3244
Avg. Estimate-0.02-0.02-0.15-0.05
Low Estimate-0.02-0.02-0.17-0.08
High Estimate-0.02-0.02-0.14-0.02
Year Ago EPS-0.21-0.07-0.48-0.15
Revenue EstimateCurrent Qtr. (Dec 2021)Next Qtr. (Mar 2022)Current Year (2021)Next Year (2022)
No. of Analysts3344
Avg. Estimate5.92M6.96M22M38.17M
Low Estimate5.7M6.87M21.7M30M
High Estimate6.07M7M22.28M50.99M
Year Ago Sales6.06M5.5M36.01M22M
Sales Growth (year/est)-2.30%26.70%-38.90%73.50%
Earnings History2020-12-302021-03-302021-06-292021-09-29
EPS Est.-0.03-0.03-0.03-0.02
EPS Actual-0.21-0.07-0.05-0.03
Difference-0.18-0.04-0.02-0.01
Surprise %-600.00%-133.30%-66.70%-50.00%
EPS TrendCurrent Qtr. (Dec 2021)Next Qtr. (Mar 2022)Current Year (2021)Next Year (2022)
Current Estimate-0.02-0.02-0.15-0.05
7 Days Ago-0.02-0.02-0.15-0.05
30 Days Ago-0.02-0.01-0.14-0.03
60 Days Ago-0.02-0.01-0.14-0.03
90 Days Ago-0.02-0.01-0.14-0.03
EPS RevisionsCurrent Qtr. (Dec 2021)Next Qtr. (Mar 2022)Current Year (2021)Next Year (2022)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesLABS.TOIndustrySector(s)S&P 500
Current Qtr.90.50%N/AN/AN/A
Next Qtr.71.40%N/AN/AN/A
Current Year68.70%N/AN/AN/A
Next Year66.70%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
6.47%% of Shares Held by All Insider
18.78%% of Shares Held by Institutions
20.08%% of Float Held by Institutions
10Number of Institutions Holding Shares

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
ETF Managers Tr-EFTMG Alternative Harvest ETF25,813,562Sep. 29, 20219.69%6,711,526
Spinnaker ETF Tr-Cannabis ETF9,164,948May 30, 20213.44%4,765,772
Global X Fds-The Global X Cannabis ETF6,350,481Oct. 30, 20212.38%1,587,620
Amplify Seymour Cannabis ETF3,247,526Sep. 29, 20211.22%844,356
Cambria ETF Tr-Cambria Cannabis ETF662,286Oct. 30, 20210.25%165,571
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by MediPharm Labs Corp.


MediPharm Reports Third Quarter 2021 Results; Announces New CEO to Start Today

MediPharm Reports Third Quarter 2021 Results; Announces New CEO to Start Today

BARRIE, Ontario, Nov. 15, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids today announced its financial results for the three and nine months ended September 30, 2021, a period of transition in establishing itself as an i... Read More...
MediPharm Labs Completes a New Cannabis Oil Delivery to German Partner Vayamed

MediPharm Labs Completes a New Cannabis Oil Delivery to German Partner Vayamed

New strategic partnership through the delivery of GMP extract to Germany for Vayamed, the medical cannabis business unit of Sanity GroupVayamed is a well-established operating medical cannabis company in Germany, where the medical cannabis market is expected to be worth €7.7 billion by 2028 according to Forbes BARRIE, Ontario, Oct. 19, 20... Read More...
Insomnia Treatment Study using MediPharm Labs CBD50 Product to Proceed to Phase 2 with Health Canada Consent

Insomnia Treatment Study using MediPharm Labs CBD50 Product to Proceed to Phase 2 with Health Canada Consent

McMaster University researchers using MediPharm Labs’ CBD50 formula and a CBD:THC 10:2 formulation, which has the same cannabinoid ratio as MediPharm Labs’ CBD25:, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-controlled trial using cannabis- oil for treatment of insomnia in major ... Read More...
MediPharm Labs Australia Receives Government Grant to Assist with International Expansion

MediPharm Labs Australia Receives Government Grant to Assist with International Expansion

Received first instalment of a government grant for $330,000AUD as part of the Australian government’s Manufacturing Modernisation program aimed at supporting manufacturers scaling their businesses.Grant to be used for automation of downstream manufacturing and scaling purification abilities.Government grant as part of broader manufacturi... Read More...
MediPharm Labs Receives Export Authorization to Ship Medical Cannabis to Brazil

MediPharm Labs Receives Export Authorization to Ship Medical Cannabis to Brazil

Completed the regulatory process required to ship medical cannabis to Brazil with import permits issued from ANVISA and export permits issued from Health Canada. Initial deliveries will be under the compassionate care program.First shipments to Brazil to be used for patient trials to collect data that may be used in future product marketi... Read More...
MediPharm Reports Second Quarter 2021 Results and Advances Pharmaceutical Strategy; Announces new Board Chair

MediPharm Reports Second Quarter 2021 Results and Advances Pharmaceutical Strategy; Announces new Board Chair

BARRIE, Ontario, Aug. 16, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in research-driven development and manufacturing of cannabis API and finished dose products today announced its financial results for the three and six months ended June 30, 2021,... Read More...
MediPharm Labs Achieves Major Pharmaceutical Manufacturing Milestone: Receives Canadian GMP Pharmaceutical Drug Establishment Licence

MediPharm Labs Achieves Major Pharmaceutical Manufacturing Milestone: Receives Canadian GMP Pharmaceutical Drug Establishment Licence

Health Canada Drug Establishment Licence allows MediPharm Labs to conduct pharmaceutical manufacturing and sale of Active Pharmaceutical Ingredients and Pharmaceutical Drug ProductsMakes MediPharm Labs a full-service pharmaceutical company that can support the global pharma entry into the drugs containing cannabis market, including in the... Read More...
MediPharm Labs Enters Research Agreement with McMaster University to Develop Drugs Containing Cannabis Candidates

MediPharm Labs Enters Research Agreement with McMaster University to Develop Drugs Containing Cannabis Candidates

MediPharm Labs’ Cannabis Drug Licence and expertise qualifies and positions the Company to supply clinical trial material, assist in investigation protocol and provide regulatory support for multiple trialsThree initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD drug candidates for multiple indicat... Read More...
MediPharm Labs Announces Voting Results From the 2021 Annual Meeting of Shareholders

MediPharm Labs Announces Voting Results From the 2021 Annual Meeting of Shareholders

BARRIE, Ontario, June 10, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced the results of matters voted on at its annual meeting of holders ... Read More...
MediPharm Labs Extends Strategic Partnership with ADREXpharma and continues to Build its Presence in Germany

MediPharm Labs Extends Strategic Partnership with ADREXpharma and continues to Build its Presence in Germany

MediPharm and ADREXpharma continue to lead the way addressing rising patient demand in the burgeoning German Medical Cannabis Market that saw sales increase 34% last year 128,000 active patients at end of 2020; German patients spent an average of $500EUR per month, finished products and extract sales continue to gain market share MediPhar... Read More...
MediPharm Labs Launches High-CBD Wellness Oils in Quebec; Ships First Order of CBD 25 and CBD 50 Formulas Now Available for Retail Sale by SQDC

MediPharm Labs Launches High-CBD Wellness Oils in Quebec; Ships First Order of CBD 25 and CBD 50 Formulas Now Available for Retail Sale by SQDC

BARRIE, Ontario, May 26, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it launched its first wellness products in Quebec and shipped its ... Read More...
MediPharm Reports First Quarter 2021 Results, Provides Strategic Update

MediPharm Reports First Quarter 2021 Results, Provides Strategic Update

BARRIE, Ontario, May 17, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation and derivative products today announced its financial results for the three months ended March 31, 2021, a period of ongoing progress i... Read More...
MediPharm Labs Sets Date to Report First Quarter 2021 Financial Results

MediPharm Labs Sets Date to Report First Quarter 2021 Financial Results

TORONTO, May 11, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce it will release first quarter financial results for the three month ... Read More...
MediPharm Labs Expands Global Portfolio in 9 Countries Including Medical and Wellness Customers for Turnkey Manufacturing and Distribution Solutions; New Supply Deal Reached With MT Pharma in Malta

MediPharm Labs Expands Global Portfolio in 9 Countries Including Medical and Wellness Customers for Turnkey Manufacturing and Distribution Solutions; New Supply Deal Reached With MT Pharma in Malta

BARRIE, Ontario, April 26, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced through its wholly owned subsidiary, it has signed a new agreeme... Read More...
MediPharm Labs Achieves Export Milestone, Ships Cannabis Oil from Australia to Germany

MediPharm Labs Achieves Export Milestone, Ships Cannabis Oil from Australia to Germany

MediPharm Labs exports commercial shipment of medical cannabis products approved by the Australian Therapeutic Goods Administration (TGA) to patients in GermanyAn export milestone for the Australian cannabis industry as an export hubGermany is one of the most heavily regulated export markets in the world, this export milestone strengthens... Read More...
European Pharmaceutical Company STADA and MediPharm Labs Begin First Sales in Germany Under Exclusive Agreement

European Pharmaceutical Company STADA and MediPharm Labs Begin First Sales in Germany Under Exclusive Agreement

BARRIE, Ontario, April 01, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced STADA Arzneimittel AG (STADA), a leading European consumer health and generics co... Read More...
MediPharm Labs Reports Fourth Quarter and Full Year 2020 Results

MediPharm Labs Reports Fourth Quarter and Full Year 2020 Results

BARRIE, Ontario, March 31, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation and derivative products today announced its financial results for the three and twelve months ended December 31, 2020. “We are e... Read More...
MediPharm Labs Sets Date to Report Fourth Quarter and Full Year 2020 Financial Results

MediPharm Labs Sets Date to Report Fourth Quarter and Full Year 2020 Financial Results

TORONTO, March 29, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce it will release fourth quarter financial results for the three and... Read More...
MediPharm Labs Expands Wellness Portfolio, Launches Next Generation of Oils with New Unique CBN Rich Formula

MediPharm Labs Expands Wellness Portfolio, Launches Next Generation of Oils with New Unique CBN Rich Formula

BARRIE, Ontario, March 26, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced a further expansion of its innovative, pharma-quality family of ... Read More...
MediPharm Labs Expands Distribution Revenue Footprint in Canada, Enters Growing Quebec Market Through New Supply Agreement

MediPharm Labs Expands Distribution Revenue Footprint in Canada, Enters Growing Quebec Market Through New Supply Agreement

Quebec marks the Company’s 7th provincial distribution supply agreementMediPharm Labs expanded distribution footprint represents potential coverage of an estimated 95%+ of retail market in CanadaMediPharm Labs will be selling its MediPharm Labs and LABS Cannabis product lines in QuebecTORONTO, March 09, 2021 -- MediPharm Labs Corp. (TSX: ... Read More...
MediPharm Labs Australia Signs Supply and Manufacturing Agreement with Cannim Australia; Announces Plan to Launch New Over-the-Counter Products

MediPharm Labs Australia Signs Supply and Manufacturing Agreement with Cannim Australia; Announces Plan to Launch New Over-the-Counter Products

TORONTO, March 08, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, is pleased to announce its wholly owned subsidiary, MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australi... Read More...
MediPharm Labs Closes Previously Announced Bought Deal Equity Financing

MediPharm Labs Closes Previously Announced Bought Deal Equity Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, March 05, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative pr... Read More...
MediPharm Labs Announces Increase to Bought Deal Equity Financing to $29 Million

MediPharm Labs Announces Increase to Bought Deal Equity Financing to $29 Million

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, March 02, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative pr... Read More...
MediPharm Labs Receives Milestone Cannabis Drug Licence to Manufacture and Distribute Pharmaceuticals Containing Cannabis Including New Drugs for Discovery Trials

MediPharm Labs Receives Milestone Cannabis Drug Licence to Manufacture and Distribute Pharmaceuticals Containing Cannabis Including New Drugs for Discovery Trials

TORONTO, Feb. 17, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, announced it has received a Cannabis Drug Licence (“CDL licence”) from Health Canada.The CDL licence is a criti... Read More...
MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors

MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors

TORONTO, Jan. 15, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced the appointment of Warren Everitt to its Board of Directors (the “Board”),... Read More...
MediPharm Labs Announces Leadership Changes

MediPharm Labs Announces Leadership Changes

BARRIE, Ontario, Dec. 10, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, today announced a senior leadership transition.To prepare the Company for its next phase of growth and ... Read More...
MediPharm Labs First to Launch THC-Free, 99% Pure CBD Isolate Consumer Sized Crystal in Canada

MediPharm Labs First to Launch THC-Free, 99% Pure CBD Isolate Consumer Sized Crystal in Canada

BARRIE, Ontario, Oct. 29, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced the launch of LABS Cannabis CBD Isolate, the first in its LABS Ca... Read More...
MediPharm Labs Sets Date to Release Third Quarter 2020 Financial Results

MediPharm Labs Sets Date to Release Third Quarter 2020 Financial Results

TORONTO, Oct. 28, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce it will release third quarter financial results for the three and n... Read More...
MediPharm Labs Enters New GMP Manufacturing Deal with Sunco Green Pharmaceutical Pty Ltd. in Australia

MediPharm Labs Enters New GMP Manufacturing Deal with Sunco Green Pharmaceutical Pty Ltd. in Australia

MediPharm and Sunco Green to bring GMP certified cannabis products to a burgeoning Australian cannabis market beginning in Q4 2020In September 2020, over 6,000 patients were approved for medical cannabis treatment in Australia an 72% increase from approvals granted nearly 1 year agoApproximately 67,000 applications for medicinal cannabis ... Read More...
MediPharm Labs Launches LABS CANNABIS, A New and Innovative Family of Health and Wellness Products

MediPharm Labs Launches LABS CANNABIS, A New and Innovative Family of Health and Wellness Products

BARRIE, Ontario, Oct. 20, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce the launch of its new “LABS Cannabis” family of health and... Read More...
MediPharm Labs Initiates Clinical Trial for Use of Cannabis to Treat Chronic Kidney Disease Patients and Improve Quality of Life

MediPharm Labs Initiates Clinical Trial for Use of Cannabis to Treat Chronic Kidney Disease Patients and Improve Quality of Life

Clinical trial will evaluate the effectiveness of MediPharm Labs proprietary GMP cannabis-derived formulations and medical products and expand MediPharm Labs owned IPIn the United States, 37 million or more than 1 in 7 adults, are estimated to have chronic kidney disease (CKD) and Worldwide, approximately 1 in 10 people suffer from kidney... Read More...
European Pharmaceutical Company STADA Enters Exclusive Medical Cannabis Partnership with MediPharm Labs

European Pharmaceutical Company STADA Enters Exclusive Medical Cannabis Partnership with MediPharm Labs

A milestone for the global cannabis industry as STADA, in partnership with MediPharm, forges the way as a large pharmaceutical company commercializing medical cannabis productsPartnership validates MediPharm Labs’ GMP pharmaceutical-quality cannabis production and, combined with STADA’s 125-year heritage and experienced marketing and sale... Read More...
MediPharm Labs Secures 100% Ownership of its Australia Subsidiary, Poised for New Wave of Global Medicinal Cannabis Growth

MediPharm Labs Secures 100% Ownership of its Australia Subsidiary, Poised for New Wave of Global Medicinal Cannabis Growth

TORONTO, Sept. 28, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it has entered into a share sale and purchase agreement (the “Buyout Agre... Read More...
MediPharm Labs Expands Denmark Revenue Opportunity, Enters New Supply Agreement with DanCann Pharma

MediPharm Labs Expands Denmark Revenue Opportunity, Enters New Supply Agreement with DanCann Pharma

TORONTO, Sept. 25, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it has entered into a new white-label supply agreement with DanCann Pharm... Read More...
MediPharm Labs Enters Brazil – Latin America's Largest Medical Cannabis Market in Partnership with XLR8 Brazil

MediPharm Labs Enters Brazil – Latin America’s Largest Medical Cannabis Market in Partnership with XLR8 Brazil

BARRIE, Ontario, Sept. 22, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced its wholly owned subsidiary MediPharm Labs Inc. will supply prem... Read More...
MediPharm Labs Enters Growing Latin American Medical Cannabis Market; Enters Supply Agreement With Cann Farm Peru

MediPharm Labs Enters Growing Latin American Medical Cannabis Market; Enters Supply Agreement With Cann Farm Peru

BARRIE, Ontario, Sept. 03, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced its wholly owned subsidiary MediPharm Labs Inc. will supply prem... Read More...
MediPharm Labs and Georgian College Complete First Research and Innovation Collaboration Driving Data and Analytics Insights

MediPharm Labs and Georgian College Complete First Research and Innovation Collaboration Driving Data and Analytics Insights

BARRIE, Ontario, Sept. 02, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., ha... Read More...
MediPharm Labs Enters Denmark Medical Cannabis Market, Secures New White-Label Supply Customers

MediPharm Labs Enters Denmark Medical Cannabis Market, Secures New White-Label Supply Customers

TORONTO, Sept. 01, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it will supply cannabis concentrate products in Denmark to two new medica... Read More...
MediPharm Labs Australia Expands Revenue Opportunity On Expanded GMP Licence

MediPharm Labs Australia Expands Revenue Opportunity On Expanded GMP Licence

BARRIE, Ontario, Aug. 19, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced that its Australian operation – MediPharm Labs Australia Pty. Ltd... Read More...
MediPharm Labs Reports Second Quarter 2020 Results, Strong Progress With International Expansion

MediPharm Labs Reports Second Quarter 2020 Results, Strong Progress With International Expansion

BARRIE, Ontario, Aug. 13, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced its financial results for the three and six months ended June 30,... Read More...
MediPharm Labs Announces Voting Results From the 2020 Annual and Special Meeting of Shareholders

MediPharm Labs Announces Voting Results From the 2020 Annual and Special Meeting of Shareholders

BARRIE, Ontario, Aug. 05, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced the results of matters voted on at its annual and special meeting... Read More...
Coming Soon.
SymbolExchangePriceChangeAs of
LABS.TO
The Toronto Stock Exchange
The Toronto Stock Exchange0.20CAD-4.88%
MLZ.F
Frankfurt Stock Exchange
Frankfurt Stock Exchange0.13EUR-1.77%
MEDIF.PK
US 'Other OTC' and Grey Market
US 'Other OTC' and Grey Market0.15USD-4.28%
MLZ.BE
Berlin Stock Exchange
Berlin Stock Exchange0.14EUR+0.07%
MLZ.D
Dusseldorf Stock Exchange
Dusseldorf Stock Exchange0.14EUR-0.07%
LABS.GO
Canadian Securities Exchange/PURE - CSE Listed & Other Canadian Listed Securities
Canadian Securities Exchange/PURE - CSE Listed & Other Canadian Listed Securities0.21CAD0.00%
MLZ.MU
Munich Stock Exchange
Munich Stock Exchange0.14EUR+0.07%
MLZ.SG
Stuttgart Stock Exchange
Stuttgart Stock Exchange0.12EUR-0.32%

Delayed data (1h)
NameAgePositionAppointed
Chris Taves
Chairman of the Board
--Chairman of the Board2021
Keith Strachan
President, Director
--President, Director2021
Bryan Howcroft
Chief Executive Officer
--Chief Executive Officer2021
Greg Hunter
Chief Financial Officer
--Chief Financial Officer2021
Warren Everitt
Chief Executive Officer of Asia Pacific, Director
--Chief Executive Officer of Asia Pacific, Director2021
Shelley Martin
Lead Independent Director
--Lead Independent Director2021
Chris Halyk
Independent Director
--Independent Director2020
Miriam McDonald
Independent Director
--Independent Director2018
Paul Tam
Independent Director
--Independent Director2019


Share this page